PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 6,699 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $120.00, for a total transaction of $803,880.00. Following the completion of the sale, the insider now owns 17,009 shares of the company’s stock, valued at approximately $2,041,080. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
NYSE:PKI opened at $118.91 on Friday. PerkinElmer, Inc. has a one year low of $62.91 and a one year high of $121.44. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.30 and a current ratio of 1.85. The firm has a market cap of $13.23 billion, a P/E ratio of 45.21, a P/E/G ratio of 1.42 and a beta of 1.37. The firm has a 50-day simple moving average of $102.67 and a 200-day simple moving average of $92.32.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.70 by $0.87. PerkinElmer had a net margin of 9.87% and a return on equity of 18.41%. The business had revenue of $811.91 million during the quarter, compared to analyst estimates of $703.32 million. During the same quarter in the previous year, the business posted $1.00 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts predict that PerkinElmer, Inc. will post 4.83 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 16th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date is Thursday, October 15th. PerkinElmer’s payout ratio is currently 6.83%.
Institutional investors have recently modified their holdings of the company. Profund Advisors LLC purchased a new position in shares of PerkinElmer in the 4th quarter worth approximately $211,000. DNB Asset Management AS grew its position in shares of PerkinElmer by 8.4% in the 2nd quarter. DNB Asset Management AS now owns 13,861 shares of the medical research company’s stock worth $1,360,000 after buying an additional 1,071 shares during the last quarter. APG Asset Management N.V. grew its position in shares of PerkinElmer by 59.8% in the 1st quarter. APG Asset Management N.V. now owns 144,148 shares of the medical research company’s stock worth $10,851,000 after buying an additional 53,918 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in shares of PerkinElmer by 6.7% in the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 8,000 shares of the medical research company’s stock worth $602,000 after buying an additional 500 shares during the last quarter. Finally, Rockland Trust Co. purchased a new position in shares of PerkinElmer in the 2nd quarter worth approximately $225,000. 93.34% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of PerkinElmer from $95.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Co lifted their price objective on shares of PerkinElmer from $105.00 to $130.00 and gave the company an “equal weight” rating in a report on Wednesday. Cfra upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating in a report on Wednesday. UBS Group lifted their price objective on shares of PerkinElmer from $95.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Finally, Robert W. Baird lifted their price objective on shares of PerkinElmer from $94.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $95.13.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Further Reading: What is Compound Interest?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.